ARTHEx Biotech Secures $87M to Advance RNA Medicines

September 17, 2025
ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million to advance its lead program ATX-01 for Myotonic Dystrophy Type 1.

ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million, announced in a press release. The funding was led by new investor Bpifrance, with participation from existing shareholders such as AdBio Partners and Columbus Venture Partners.

The proceeds will be used to further the global clinical development of ARTHEx's lead program, ATX-01, which targets Myotonic Dystrophy Type 1 (DM1). ATX-01 is an anti-miR oligonucleotide designed to inhibit microRNA23b (miR-23b), a natural repressor of MBNL protein expression. This mechanism aims to increase MBNL production, decrease toxic DMPK mRNA, and improve splicing abnormalities in DM1 patients.

The financing will support the ongoing interventional Phase I/IIa ArthemiRTM study and prepare for an open-label extension to support a registrational study, further advancing ARTHEx's pipeline of targeted RNA medicines.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

09/17
Rulebase Secures $2.1 Million to Automate Fintech Back-Office Tasks
09/17
CodeRabbit Secures $60 Million to Enhance AI Code Review Platform
09/17
Lila Sciences Secures $235 Million to Expand AI-Driven Research
09/16
Spara Launches AI Platform with $15M Seed Funding
09/16
SDG Corporation Acquires Hub City Media to Strengthen IAM Solutions

More from: Life Sciences

09/17
Lila Sciences Secures $235 Million to Expand AI-Driven Research
09/17
Gyala Therapeutics Unveils Promising CAR-T Therapy Targeting CD84
09/16
Senhwa Biosciences Enters Immunotherapy Market with New Clinical Trial
09/16
Mount Sinai Opens AI Research Lab for Cardiac Catheterization
09/16
ProofPilot Acquires Lokavant to Enhance Clinical Trial Analytics

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like